Results 221 to 230 of about 34,445,663 (284)

Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data. [PDF]

Mayo Clin Proc Digit Health
Chabassier A, Vittrant B, Binon P, Scornet E, Josse J.   +4 more
europepmc   +1 more source

Sensor‐Detected Hypoglycaemia Is Associated With Inflammatory Protein and Immune Cell Alterations in People With Diabetes: Findings From the Hypo‐METRICS Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Experimental hypoglycaemia induces a persistent inflammatory response. We investigated whether real‐life sensor‐detected hypoglycaemia (SDH) is associated with immune parameters in people with Type 1 and Type 2 diabetes and explored potential differences between the groups.
Mandala Ajie, Namam Ali, Marijn S. Hendriksz, Patrick Divilly, Marloes J. Rietveld, Evertine J. Abbink, Pratik Choudhary, Julie Maria Bøggild Brøsen, Ulrik Pedersen‐Bjergaard, Rory J. McCrimmon, Mark Evans, Julia K. Mader, Bastiaan E. de Galan, Rinke Stienstra, Cees J. Tack, on behalf of the Hypo‐RESOLVE Consortium   +15 more
wiley   +1 more source

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention. [PDF]

J Cosmet Dermatol
Kruglikov IL.
europepmc   +1 more source

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang, Ting Zhou, Huilin Tang, Yiwen Lu, Dazheng Zhang, Jiajie Chen, Tianchu Lyu, Kai Zheng, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Predicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN‐1 Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To assess change in long‐term predicted 10‐year cardiometabolic risk (Type 2 diabetes [T2D] and cardiovascular disease [CVD]) in adults with overweight or obesity without T2D. Methods This post hoc analysis used data from ATTAIN‐1, a Phase 3 trial in adults (≥ 18 years) with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 with
Shraddha Shinde, Florian Kahles, Simona Vasileva‐Metodiev, Ryan Griffin, Hong Liu‐Seifert, Jeremie Lebrec, Neena A. Xavier, Runjia Li, Suzanne R. Klise, Ambrish Singh, Jens Aberle   +10 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. [PDF]

Arthritis Rheumatol
Haberman RH, Rice AL, Chen K, Scher U, Thib S, Scher JU, Eder L.   +6 more
europepmc   +1 more source

Effect of Sotagliflozin on Kidney Function and Cardio‐Kidney‐Metabolic Parameters Across Baseline eGFR Subgroups in Patients With Type 2 Diabetes and Stage 4 CKD

Diabetes, Obesity and Metabolism, EarlyView.
Vikas S. Sridhar, Luxcia Kugathasan, Manon Girard, Michael J. Davies, David Z. I. Cherney   +4 more
wiley   +1 more source

Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the effect of semaglutide on body composition and physical function. Materials and Methods The phase 3b STEP UP trial randomised adults with body mass index ≥ 30 kg/m2 to once‐weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg or placebo for 72 weeks.
Jøran Hjelmesæth, Suhas Bhat, W. Timothy Garvey, Kristoffer Jensen Kolnes, Jennifer Linge, Ildiko Lingvay, Niklas Kahr Rasmussen, Julio Rosenstock, Sean Wharton   +8 more
wiley   +1 more source

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

JAMA Netw Open
Sørensen KK, Møller FT, Yazdanfard PDW, Hasselbalch R, Kragholm KH, Andersen MP, Torp-Pedersen C.   +6 more
europepmc   +1 more source

Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases. [PDF]

Dermatol Ther (Heidelb)
Kwiek B, Sieczych J, Łukowska K, Ambroziak M.   +3 more
europepmc   +1 more source